Poor
Not Aligned
Patient Risk:
Low
Summary
The provided label excerpts contain only section headings (no prescribing text). Therefore, none of the substantive drug-label-related claims can be verified, and non-label topics (pricing/patent/biosimilar pipeline) are not supported by the supplied FDA label content.
Category Scores
Accurate Statements
Unsupported Statements
Abemaciclib is a prescription medication used to treat hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2) advanced or metastatic breast cancer in combination with endocrine therapy.
No indication text was provided from label section '1 INDICATIONS AND USAGE'—only headings—so the claim cannot be verified against the supplied labeling.
Abemaciclib is used to treat HR+, HER2-negative advanced or metastatic breast cancer with recurrence or progression after endocrine therapy in postmenopausal women.
No indication text was provided from label section '1 INDICATIONS AND USAGE'—only headings—so the claim cannot be verified against the supplied labeling.
The average wholesale price (AWP) of abemaciclib is around $13,500 per month, according to Express Scripts.
Pricing/AWP information and third-party payer source statements are not contained in the provided label excerpts.
The patent for abemaciclib is set to expire in 2030.
Patent expiration information is not part of the provided FDA label excerpts.
Once the patent expires, generic versions of abemaciclib may become available, which could lead to decreased costs.
Generic availability and cost-impact predictions are not addressed in the provided label excerpts.
There is no approved biosimilar version of abemaciclib available yet.
Biosimilar approval status is not provided in the supplied label excerpts.
Several biosimilars of abemaciclib are in development.
Biosimilar development/pipeline information is not provided in the supplied label excerpts.
Contradictions
Important Omissions
FDA label safety-relevant content (e.g., '4 CONTRAINDICATIONS', '5 WARNINGS AND PRECAUTIONS' including any boxed warning, '2 DOSAGE AND ADMINISTRATION', and '8 USE IN SPECIFIC POPULATIONS') necessary to evaluate dosing and safety alignment for the provided claims.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
The supplied evaluation concerns label-alignment of factual statements, but the provided excerpts do not include safety or dosing sections; no specific unsafe dosing or safety instructions were claimed in the extracted claims.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
No provided FDA label prescribing text exists for 'INDICATIONS AND USAGE' and safety/dosing sections; multiple claims (pricing/patent/biosimilar status/pipeline) are not supported by the supplied label excerpts.
Suggested Improvement
Provide the actual FDA label text for the relevant sections (at minimum '1 INDICATIONS AND USAGE' and, for safety review, '2 DOSAGE AND ADMINISTRATION', '4 CONTRAINDICATIONS', '5 WARNINGS AND PRECAUTIONS', and '8 USE IN SPECIFIC POPULATIONS') or remove unsupported non-label statements (AWP, patent expiry, generic/biosimilar pipeline/status) from the response.